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ABSTRACT 
INTRODUCTION: Cardiovascular (CV) reactivity to psychological stress has been implicated in the 
development and exacerbation of cardiovascular disease (CVD).  Although high CV reactivity 
traditionally is thought to convey greater risk of CVD, the relationship between reactivity and clinical 
outcomes is inconsistent, and may depend on the patient population under investigation.  The present 
study examined CV reactivity in patients with heart failure (HF) and its potential association with long-
term clinical outcomes. 
METHODS:  199 outpatients diagnosed with HF, with ejection fraction <40%, underwent an evaluation 
of blood pressure (BP) and heart rate reactivity to a laboratory-based simulated public-speaking stressor.  
Cox proportional hazards regression models were used to examine the prospective association between 
BP and heart rate reactivity on a combined endpoint of death or CV hospitalization over a 5-year median 
follow-up period.   
RESULTS:  Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) reactivity, quantified 
as continuous variables, were inversely related to risk of death or CV hospitalization (p’s<.01) after 
controlling for established risk factors, including HF disease severity, etiology, and age.  In similar 
models, heart rate reactivity was unrelated to outcome (p=0.12).  In models with tertiles of reactivity, high 
SBP reactivity, compared to intermediate SBP reactivity, was associated with lower risk (Hazard Ratio = 
.498, 95% CI [.335, .742], p =.001); while low SBP reactivity did not differ from intermediate reactivity.  
For DBP, high reactivity was marginally associated with lower risk compared to intermediate DBP 
reactivity (HR = .767, 95% CI [.515, 1.14], p =.193), while low DBP reactivity was associated with 
greater risk (HR = 1.49, 95% CI [1.027, 2.155], p =.0359). No relationship of heart rate reactivity to 
outcome was identified. 
CONCLUSIONS:  For HF patients with reduced ejection fraction, a robust increase in BP evoked by a 
laboratory-based psychological challenge was associated with lower risk for adverse CVD events, and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
may be a novel and unique marker of left ventricular systolic reserve that is accompanied by a more 
favorable long-term prognosis. 
Key words: heart failure; stress; blood pressure reactivity; hospitalizations; death. 
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ABBREVIATIONS: 
BDI – Beck Depression Inventory 
BP – Blood Pressure 
CABG – Coronary Artery Bypass Graft Surgery 
CHD – Coronary Heart Disease 
CVD – Cardiovascular Disease 
DBP – Diastolic Blood Pressure 
HF – Heart Failure 
HR – Hazard Ratio 
LVEF – Left Ventricular Ejection Fraction 
NT-proBNP - N-Terminal pro B-type Natriuretic Peptide 
PCI – Percutaneous Coronary Intervention 
SBP – Systolic Blood Pressure 
SNS – Sympathetic Nervous System 
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Exaggerated cardiovascular (CV) responses to stress have long been considered as 
potentially deleterious to cardiovascular health.  Although this notion has been entertained and 
supported by anecdotal evidence since antiquity, its foundation as a scientific concept did not 
arise until the beginning of the 20
th
 century (1).  In general, acute psychological stress is 
associated with “fight/flight” mobilization of the CV system via sympathetic nervous system 
(SNS) activation, typically resulting in a marked increase in blood pressure (BP).   Laboratory-
based evaluation of “cardiovascular reactivity” is one strategy that has been widely adopted to 
help understand the implications of individual differences in the magnitude of the stress response 
for CV health (2-6).  Reactivity is typically defined by changes in CV responses compared to 
resting levels during psychological stress.  Prospective studies have shown that relatively healthy 
men and women exhibiting greater BP reactivity are at increased risk for the development of 
hypertension and atherosclerotic cardiovascular disease (CVD), compared to those who exhibit a 
less pronounced response (4).  In patients with ischemic heart disease (IHD), high BP reactivity 
to laboratory mental stressors has been linked to an increased incidence of myocardial ischemia 
and greater risk for untoward cardiac events (7, 8). 
To our knowledge, only one study to date has examined the association of CV reactivity 
with clinical outcomes in patients with heart failure (HF).  Kupper and colleagues examined the 
association between BP responses to a laboratory-based, simulated public speaking task and 
mortality over a 4-year follow-up period in 100 patients with systolic HF (9).  High BP reactivity 
was not associated with increased mortality risk, while individuals who exhibited low diastolic 
blood pressure (DBP) responses had a twofold increased risk of mortality compared to those who 
exhibited intermediate DBP responses.  The present study was designed to further examine the 
relation of CV reactivity to mental stress to adverse clinical outcomes in patients with HF.  
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Utilizing a simulated public speaking mental challenge, we also examined the association 
between BP and heart rate reactivity and a composite endpoint of CV hospitalization or death 
over a median 5-year follow-up period in patients with HF and reduced ejection fraction (EF).   
METHODS 
Participants 
Participants were recruited from the HF clinics at Duke University Medical Center and 
the University of North Carolina at Chapel Hill, from January 2000 through December 2002.  
Approximately 500 patients that met our eligibility criteria were approached; 219 of these 
patients consented to participate and were enrolled.  For 204 of these participants we obtained a 
plasma NT-proBNP value necessary to control for HF disease severity in our analyses, and of 
these 204 we completed cardiovascular reactivity testing on 199, which comprise the present 
study sample.  Inclusion criteria for study participation were HF with New York Heart 
Association Class II-III symptoms of at least 3-months duration; and left ventricular ejection 
fraction (LVEF) of 40% or less as assessed by left ventriculography, nuclear gated blood pool or 
perfusion study, or echocardiography, within 6 months of study enrollment. Potential participants 
were excluded if they were pacemaker-dependent, had uncontrolled hypertension (BP > 180/105 
mm Hg), experienced a myocardial infarction (MI) within the past 3 months, or underwent 
percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) within 
the past 3 months, had HF due to a condition other than ischemic or non-ischemic dilated 
cardiomyopathy, such as uncorrected primary valvular disease or hypertrophic or restrictive 
cardiomyopathy, had uncorrected thyroid heart disease, had a persistent tachyarrhythmia, or had 
a life limiting or complicated illness including cancer, renal dysfunction, hepatic dysfunction, or 
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dementia. Participants who were pregnant, had atrial fibrillation, reported alcohol or drug abuse 
within 12 months, or were unable to comply with the assessment procedure or to provide 
informed consent were excluded. The study was approved by the Institutional Review Board at 
Duke University Medical Center, where all assessments were performed. Written informed 
consent was obtained from all participants before their participation. 
Clinical Status 
 Clinical information and medical history were obtained from medical records.  
Medications were documented as medications being taken at the time of baseline assessments.   
N-Terminal pro B-type Natriuretic Peptide (NT-proBNP) 
Blood was collected from an antecubital vein into a phlebotomy tube containing EDTA. 
Samples were placed on ice, cold-centrifuged at 1000 X g for 10 min. NT-proBNP 
measurements were performed using an electrochemiluminescence immunoassay in accordance 
with the manufacturer’s instructions (Elecsys proBNP, Roche Diagnostics Corporation, 
Indianapolis, IN).  
Left Ventricular Ejection Fraction (LVEF) 
LVEF was determined by two-dimensional echocardiography.  Apical 4-chamber and 2-
chamber images of the heart were acquired by a single sonographer using an Acuson (Mountain 
View, California) ultrasound machine and were stored as digital loops.  The endocardial borders 
of the LV in the 2 views were traced by a single experienced echocardiography specialist using 
customized off-line software (Access Point 2000, Freeland Systems, LLC, Westfield, Indiana), 
and ventricular volumes and LVEF were computed using the biapical Simpson’s rule.  
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Depression Symptoms 
Depression symptoms were assessed using the Beck Depression Inventory (BDI), a 21-
item self-report measure (10, 11).  Elevated symptoms of depression measured by the BDI are 
associated with increased risk of adverse events in patients with HF (12, 13). 
Blood Pressure (BP) and Heart Rate  
BP was assessed using a Suntech 4240 blood pressure monitor, which determined systolic (SBP) 
and diastolic (DBP) blood pressure during the testing protocol. This computer-based monitor 
measures heart rate using a standard electrocardiogram. 
Mental Stress Testing  
Resting Baseline:  During the first 20 minutes, BP measurements were initiated every 5 minutes 
to acclimatize participants to the BP cuff. uring the last 5 minutes of the baseline rest period BP 
and heart rate were recorded every minute, resulting in a total of five sets of readings that were 
averaged (mean) to represent resting baseline.   
Public Speaking Task:  Participants were asked to choose one of the following topics to discuss 
during a 3-minute speech: (i) Does the healthcare system in the U.S. need to be changed? (ii) 
Who or what is to blame for the epidemic of school shootings?  (iii) Is the death penalty needed 
in modern America?  Participants were allowed 3 minutes to prepare their speech, without 
making written notes.  Subsequently, participants presented their speech for 3-minutes to a 
research staff member who was seated in the room with them, with participants also instructed 
that a video camera and intercom system would allow others members of the research team 
outside the testing room to see and hear their speech.  BP and heart rate were measured once per 
minute over the 3-minute speech task, and BP and heart rate reactivity were defined as the 
difference between resting baseline and the mean of the three speech values. 
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Long-term Follow-up of Vital Status and Hospitalizations 
Participants’ medical records were reviewed on a yearly basis, over a median period of 5 
consecutive years from baseline (with a range of 4 to 7 years and no losses to follow-up), on the 
anniversary of their baseline assessments.  Patients also were contacted annually by mail and 
asked to indicate whether they had been hospitalized during the past year, and to provide consent 
for retrieval of their hospitalization records.  The primary endpoint was defined as the time to 
cardiovascular hospitalization or death (whichever occurred first) within the follow-up period.  
Patient mortality was verified through hospital and Emergency Medical Services records. 
Cardiovascular hospitalizations included hospitalizations for MI, stroke, worsening HF, PCI, 
cardiac surgery including CABG, and heart transplantation.   
Statistical Methods 
Cox proportional hazards regression models were used to examine the relationship 
between cardiovascular reactivity (BP and heart rate responses to public speaking, specified as 
continuous variables) and events (mortality and hospitalizations) during the follow-up period.  
HF etiology (ischemic or non-ischemic), NT-proBNP, LVEF, age, and BDI score were evaluated 
in the originally planned models, together with resting baseline BP and heart rate values.  In 
order to assess the robustness of the planned models, other potential factors (including NYHA 
class, diabetes, hypertension, hypercholesterolemia, myocardial infarction, smoker, glomerular 
filtration rate, defibrillator, beta-blocker, diuretic, angiotensin converting enzyme (ACE)-
inhibitor, nitrate, warfarin, statin) were eligible for entry into the models by stepwise selection 
(SLE=.1).  In order to better understand associations with continuous variables, the regression 
models were re-fit using BP and heart rate responses classified into low, intermediate, and high 
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tertiles of reactivity.  For Cox regression analyses, NT-proBNP was expressed as NT-
proBNP/1000, LVEF was expressed as LVEF/10, SBP was expressed as SBP/10, DBP as 
DBP/10, heart rate as heart rate/10, and age was expressed as age/10.  Kaplan-Meier plots were 
constructed to illustrate the association between tertiles of BP reactivity indices (SBP and DBP) 
and event free survival. 
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RESULTS 
Sample Demographics and Outcomes 
Table 1 summarizes the demographic and clinical characteristics of our study sample.  At 
the time of our baseline study assessments, participants had been living with a diagnosis of HF 
for an average of 5.3 ± 4.8 years.  Over the median follow up period of 5 years, there was a total 
of 155 first events (82% of the sample), including 72 CVD hospitalizations and 83 deaths. 
It is of note that there were no missing data for the study sample and no participants were lost to 
follow-up. 
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Table 1. Demographic and clinical characteristics of the Study Sample 
Characteristic (N=199) Mean ± SD or % 
Age (years) 57.0 ± 12.2 
Body Mass Index (kg/ m
2
) 31.3 ± 6.9 
Race (% White) 50% 
Gender (% Female) 32% 
BDI Depression Score 10.7 ± 7.3 
NR-proBNP (pg/ml) 1717.0 ± 2716.5 
LVEF 31.9 ± 11.4 
Baseline SBP (mmHg) 99.9 ± 18.4 
Baseline DBP (mmHg) 60.8 ± 10.7 
Baseline Heart Rate (bpm) 66.5 ± 11.5 
SBP Reactivity (mmHg) 19.4 ± 14.3 
DBP Reactivity (mmHg) 14.7 ± 9.2 
Heart Rate Reactivity (bpm) 6.5 ± 6.0 
Etiology ( % ischemic) 43.5 
Beta Blocker (% usage) 87.5 
Diabetes (%) 44.0 
Current Smoker (%) 16.5 
Current Alcohol use (%) 22.8 
Anti-coagulant (%) 29.0 
Antidepressant (%) 20.5 
Cholesterol Medication (%) 46.5 
Implantable Defibrillator (%) 7.5 
Diuretic (%) 92.5 
ACE inhibitor (%) 86.5 
Pacemaker (%) 28.5 
 
Associations between reactivity to stress and death or cardiovascular hospitalization 
Systolic Blood Pressure (SBP) Reactivity. 
Cox Proportional Hazards Regression Models (Table 2) in which SBP reactivity was 
specified as a continuous variable revealed that increasing SBP reactivity to public speaking was 
associated with reduced incidence of death or cardiovascular hospitalization (HR, 0.859; 95% 
CI, 0.765 – 0.965; p = 0.01) in models which included etiology, LVEF, NT-proBNP and resting 
SBP.  Extended models which also included depression and use of diuretics still revealed 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12 
 
elevated SBP reactivity to stress to be associated with a lower risk of death or cardiac event (HR, 
0.860; 95% CI, 0.765 – 967; p = 0.012).    
Table 2. Systolic Blood Pressure Response to Mental Stress: Cox Proportional Regression Analyses 
for Death or Cardiac Hospitalization 
Variable Planned Model
*
 HR 
(95% CI) 
P Value Extended Model
†
 HR 
(95% CI) 
P Value 
Etiology 1.713 (1.241 – 2.366) 0.001 1.759 (1.273 – 2.429) 0.001 
LVEF/10 0.829 (0.706 – 0.973) 0.022 0.808 (0.686 – 0.951) 0.011 
ProBNP/1000 1.060 (1.011 – 1.111) 0.016 1.069 (1.019 – 1.122) 0.007 
Baseline SBP/10 1.016 (0.923 – 1.115) 0.731 1.033 (0.992 – 1.133) 0.485 
SBP Reactivity/10 0.859 (0.765 – 0.965) 0.010 0.860 (0.765 – 0.967) 0.012 
Depression - - 1.034 (1.012 – 1.056) 0.002 
Diuretics - - 2.161 (1.053 – 4.436) 0.036 
HR = Hazard ratio; CI = confidence Interval; LVEF = left ventricular ejection fraction; BNP = Brain 
Natriuretic Peptide. 
*
 Adjusted for etiology, LVEF, ProBNP, baseline SBP and SBP reactivity to stress 
task. 
†
Adjusted for the variables in the a priori planned model, as well as depression score and diuretic 
use. 
To better understand how the magnitude of SBP reactivity was related to event free 
survival, SBP reactivity was examined in terms of tertiles, representing Low (4±6 mm Hg), 
Intermediate (19±4 mm Hg) and High (35±9 mm Hg) SBP reactivity to the public speaking task.  
The clinical characteristics of participants comprising these tertiles are summarized in Table 3. 
 
Table 3. Clinical Characteristics of study sample by Tertiles of SBP Reactivity. 
Characteristic (N=199) High Reactors 
(N=67) 
Intermediate 
Reactors (N=65) 
Low Reactors 
(N=67) 
P value 
Age (years) 57.7 ± 11.7 56.0 ± 12.5 57.1 ± 12.8 0.73 
BMI (kg/m
2
) 30.5 ± 6.49 32.19 ± 7.13
a,c
 30.5 ± 7.06 0.58 
Race (% White) 45.2 46.2 58.5 0.14 
Gender (% Female) 32.3 29.2 33.8 0.94 
Pro BNP (pg/ml) 1110.5 ± 1597.4 1830.7 ± 2715.3 2350.0 ± 3480.2
a
 0.03 
LVEF (%) 33.4 ± 10.1 31.6 ± 12.7 29.9 ± 10.9
a
 0.10 
Etiology (% ischemic) 40.3 44.6 43.1 0.91 
Diabetes (%) 32.3 46.2 50.8
a
 0.07 
Beta Blocker (%) 90.3 89.2 83.1 0.50 
a
 – significantly different from high reactors (p < .05); b – significantly different from intermediate 
reactors (p < .05); 
c
 – significantly different from low reactors (p < .05) 
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The Cox Proportional Hazards Regression Models were refit using Intermediate SBP 
Reactivity as the reference for understanding risk.  Compared to Intermediate Reactivity, High 
SBP Reactivity was associated with lower risk of subsequent cardiovascular hospitalization or 
death (HR = .498, 95% CI [.335, .742], p =.001), while Low SBP Reactivity was similar to 
Intermediate SBP Reactivity (HR = .879, 95% CI [.609, 1.268], p =.4901).  These effects are 
illustrated by the Kaplan-Meier survival curves displayed in Figure 1. 
 
Figure 1. Event-free Survival by Systolic Blood Pressure Response in Tertiles  Event-free 
survival over a median 5-year follow-up period for High (blue line), Intermediate (red line) and Low (green line) 
SBP reactivity to a public speaking stressor. 
 
Diastolic Blood Pressure (DBP) Reactivity. 
Results for DBP reactivity (Table 4), specified as a continuous variable, were similar to 
those for SBP reactivity.  These regression models showed that greater DBP reactivity to public 
speaking was associated with lower risk of cardiovascular hospitalization or death (HR, 0.759; 
95% CI, 0.634 – 0.910; p < 0.003) in models which included etiology, LVEF, NT-proBNP and 
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resting DBP.  Extended models that added BDI depression scores and use of diuretics confirmed 
that elevated DBP reactivity was robustly associated with lower risk of cardiovascular 
hospitalization or death (HR, 0.765; 95% CI, 0.638 – 0.919 p = 0.004).  
 
Table 4. Diastolic Blood Pressure Response to Mental Stress: Cox Proportional Regression 
Analyses for Death or Cardiac Hospitalization.  
Variable Planned Model
*
 HR 
(95% CI) 
P Value Extended Model
†
 HR 
(95% CI) 
P Value 
Etiology 1.648 (1.173 – 2.316) 0.004 1.687 (1.204 – 2.363) 0.002 
LVEF/10 0.845 (0.722 – 0.989) 0.036 0.825 (0.702 – 0.969) 0.020 
ProBNP/1000 1.072 (1.022 – 1.124) 0.004 1.081 (1.030 – 1.135) 0.002 
Baseline DBP/10 1.002 (0.853 – 1.176) 0.985 1.016 (0.864 – 1.196) 0.846 
DBP Reactivity /10 0.759 (0.634 – 0.910) 0.003 0.765 (0.638 – 0.919) 0.004 
Depression - - 1.033 (1.011 – 1.055) 0.003 
Diuretics - - 2.083 (1.014 – 4.278) 0.046 
HR = Hazard ratio; CI = confidence Interval; LVEF = left ventricular ejection fraction; BNP = Brain 
Natriuretic Peptide. 
*
 Adjusted for etiology, LVEF, ProBNP, baseline DBP and DBP reactivity to stress 
task. 
†
Adjusted for the variables in the a priori planned model, as well as depression score and diuretic 
use. 
Again, to better understand how DBP reactivity was related to event free survival, 
tertiles, representing Low (5±4 mm Hg), Intermediate (14±3 mm Hg) and High (26±5 mm Hg) 
DBP reactivity were examined.  The clinical characteristics of participants comprising these 
tertiles are summarized in Table 5. 
Table 5. Clinical Characteristics of study sample by Tertiles of DBP Reactivity. 
Characteristic (N=199) High Reactors 
(N=63) 
Intermediate 
Reactors (N=71) 
Low Reactors 
(N=66) 
P value 
Age (years) 56.6 ± 12.4 57.5 ± 12.7 56.6 ± 12.8 0.89 
BMI (kg/m
2
) 31.0 ± 6.75 31.6 ± 7.60 31.3 ± 6.61 0.90 
Race (% White) 52.4 50.8 47.0 0.82 
Gender (% Female) 30.2 33.8 31.8 0.90 
Pro BNP (pg/ml) 1236.1 ± 2023.0 1761.9 ± 3048.7 2127.6 ± 2887.9 0.17 
LVEF (%) 33.3 ± 10.7 31.2 ± 12.3 32.3 ± 11.0
a
 0.49 
Etiology (% ischemic) 38.1 46.5 45.5 0.58 
Diabetes (%) 34.9 40.8 56.1
a
 0.04 
Beta Blocker (%) 92.1 81.7 89.4 0.17 
a
 – significantly different from high reactors (p < .05); b – significantly different from intermediate 
reactors (p < .05); 
c
 – significantly different from low reactors (p < .05) 
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Compared to Intermediate DBP Reactivity, High DBP Reactivity was marginally 
associated with lower risk of subsequent cardiovascular hospitalization or death (HR = .767, 
95% CI [.515, 1.14], p =.193), while Low DBP Reactivity was associated with greater risk (HR 
= 1.49, 95% CI [1.027, 2.155], p =.0359).  These effects are illustrated by the Kaplan-Meier 
survival curves displayed in Figure 2. 
 
Figure 2. Event-free Survival by Diastolic Blood Pressure Response in Tertiles  Event-free 
survival over a median 5-year follow-up period for High (blue line), Intermediate (red line) and 
Low (green line) DBP reactivity to a public speaking stressor.   
Heart Rate Reactivity 
In contrast to BP, elevated heart rate reactivity to public speaking was not clearly 
associated with lower incidence of cardiovascular hospitalization or death (HR, 0.813; 95% CI, 
0.613 – 1.078; p = 0.15) in models which included etiology, LVEF, ProBNP and Baseline heart 
rate (Table 6). In the extended model for heart rate, only depression met criteria for inclusion; 
however, results for heart rate were virtually unchanged (HR=0.816; 95% CI, 0.614 – 1.085; p = 
0.162).  
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Table 6. Heart Rate Response to Mental Stress: Cox Proportional Regression Analyses for Death or 
Cardiac Hospitalization.  
Variable Planned Model
*
 HR 
(95% CI) 
P Value Extended Model
†
 HR 
(95% CI) 
P 
Value 
Etiology 1.783 (1.286 – 2.472) 0.001 1.780 (1.281 – 2.474) 0.001 
LVEF/10 0.809 (0.691 – 0.947) 0.009 0.797 (0.677 – 0.938) 0.006 
ProBNP/1000 1.065 (1.015 – 1.117) 0.010 1.077 (1.025 – 1.131) 0.003 
Baseline Heart Rate/10 1.266 (1.086 – 1.476) 0.003 1.233 (1.058 – 1.437) 0.007 
Heart Rate Reactivity/10 0.813 (0.613 – 1.078) 0.150 0.816 (0.614 – 1.085) 0.162 
Depression - - 1.033 (1.010 – 1.055) 0.004 
HR = Hazard ratio; CI = confidence Interval; LVEF = left ventricular ejection fraction; BNP = Brain 
Natriuretic Peptide. 
*
 Adjusted for etiology, LVEF, ProBNP, baseline heart rate and heart rate reactivity 
to stress task. 
†
Adjusted for the variables in the a priori planned model, as well as depression score. 
 
DISCUSSION 
 In a study sample of stable HF outpatients with reduced LVEF, we examined whether 
cardiovascular reactivity to a laboratory-based simulated public speaking challenge was 
associated with subsequent risk of adverse clinical outcomes, defined by the composite endpoint 
of cardiovascular hospitalization or death.  The results showed that greater BP reactivity was 
associated with a lower risk of adverse clinical outcomes, even after taking into account 
established risk factors.  For SBP reactivity, patients comprising the highest one third of the 
distribution of SBP responses to the challenge were at approximately half the hazard of an 
adverse event compared to those exhibiting less marked SBP increases.  For DBP, the 
associations with reactivity were directionally similar, but most marked when contrasting those 
exhibiting the lowest DBP reactivity, for whom the hazard of an adverse event was about 50% 
greater compared to those exhibiting more robust DBP increases.   
In contrast to the widely held viewpoint that high cardiovascular reactivity increases the 
risk of developing or exacerbating CVD (4), our findings suggest that for patients with HF and 
reduced LVEF, high BP reactivity is associated with lower risk, and indeed low BP reactivity is 
associated with increased risk.  In this respect, our observations show an overall pattern that is 
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consistent with the findings reported by Kupper and colleagues who found low DBP reactivity to 
be associated with increased risk of mortality in a study sample of 100 HF patients with reduced 
LVEF (9).  While the prevailing research hypothesis regarding cardiovascular reactivity has been 
that greater reactivity is deleterious to cardiovascular health, a more recent body of evidence has 
brought this unidirectional conceptualization into question.  For example, attenuated 
cardiovascular reactivity has been observed in individuals who display health behaviors 
associated with heightened CVD risk, including obesity, eating disorders, smoking and substance 
abuse (14-19).  Depression, which recently has been recognized as another risk factor for the 
development and exacerbation of CVD (20), also has been found to be characterized by blunted 
cardiovascular reactivity (16, 21-23).   These findings highlight the issue of whether stress 
reactivity’s link to CVD is a pathophysiologic mechanism, or more simply a bio-behavioral risk 
marker (24).  Results of the present study suggest that the answer to this question may be 
dependent upon the population under study.  In patients with borderline hypertension, for 
example, there is a characteristic BP hyper-reactivity to laboratory-based psychological 
challenge that is related to the subsequent development of hypertension (25).  Potential 
mechanisms include metabolic autoregulation leading to vascular hypertrophy and vascular 
rarefaction (26), and SNS overdrive resulting in down-regulation of cardiac and vascular beta-
adrenergic receptors (27), all promoting a hemodynamic shift to elevated systemic vascular 
resistance that results in sustained hypertension.  High BP reactivity also has been linked to 
adverse outcomes in patients with stable coronary heart disease (CHD) (7, 8).  These patients not 
only show increased blood pressure and heart rate responses during laboratory mental stress 
testing, but also may be more likely to exhibit myocardial ischemia.  This is presumably a 
manifestation of increased myocardial oxygen demands accompanied by compromised oxygen 
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supply caused by SNS-mediated vasoconstriction of diseased coronary vessels (28, 29).  
Provocation of myocardial ischemia in CHD patients has been shown to be an independent 
predictor of adverse clinical events, and also may reflect a mechanism that increases 
vulnerability to psychological stress in patients with CHD (30, 31).  Stress-induced myocardial 
ischemia is typically abolished following surgical coronary revascularization.  In a study of 521 
CHD patients who had undergone CABG, high cardiovascular reactivity was associated with a 
reduced risk of clinical cardiovascular events (32).  The authors interpreted this finding as 
indicative of the ability of the restored left ventricle to respond to the challenge of a mental stress 
task.  We speculate that high BP reactivity in HF patients with reduced EF is also a negative risk 
marker by virtue of it representing left ventricular functional reserve that becomes apparent 
under the laboratory-evoked circumstance of psychological challenge.  From this perspective, a 
robust increase in BP to psychological challenge is conceptualized as an adaptive healthy 
response that is summoned by the BP seeking properties of the central nervous system (33). 
 Examination of the Kaplan-Meier event-free survival curves (Figures 1 & 2) shows that 
the separation associated with BP reactivity emerged quite early in the clinical follow-up phase 
that succeeded the CV reactivity assessment.  This observation is consistent with the 
interpretation that a robust BP response is indicative of a relatively healthy cardiac functional 
capacity, while a weak BP response may indicate limited cardiac reserve.  Indeed, participants 
categorized as high BP reactors tended to have somewhat less severe HF disease biomarkers 
(Tables 3 & 5).  However, our statistical models controlled for established risk factors, including 
HF disease severity, comorbidities, and medication use, thereby indicating the BP reactivity was 
independently related to clinical outcomes. The laboratory mental stress test protocol may 
therefore reveal the capacity for cardiovascular adaptation to environmental challenges that may 
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further stratify HF disease severity beyond that provided by established biomarkers such as NT-
proBNP and LVEF.   
The ability to adapt to physical challenge has been studied much more widely in HF 
patients.  Cardiopulmonary exercise testing is considered the gold standard for the assessment of 
functional capacity, and is a predictor of mortality independent of other established biomarkers 
(34).  The six-minute walk test has also been used as a simple approach to assessing functional 
capacity that also can help stratify risk in HF patients and guide their medical management (35).  
Unfortunately, we did not assess functional capacity using either of these approaches, so it is 
unknown whether cardiovascular reactivity to psychological challenge may provide unique risk 
stratification compared to that provided by physical assessments of functional capacity.   
 Several additional limitations should be considered when assessing our study 
observations.  Participants were stable HF outpatients taking a broad range of cardiovascular 
medications that may have impacted the study findings.  Although medications and 
comorbidities were addressed in statistical models, their potential effects cannot be completely 
accounted for.  Notably, approximately 90% of the study participants were taking beta-blocker 
medications, which would limit heart rate responses to the psychological challenge, but leave BP 
responses unaltered (36).  Therefore, our findings for BP but not heart rate reactivity may be due, 
in part, to the effects of these medications.  Another important limitation of our study design is 
the uncertainty as to whether our observations indicate causal relationships between CV 
reactivity and adverse clinical outcomes.  Indeed, it is unlikely that a highly reactive response 
conveys some cardio-protective function in the context of HF, but more likely that it reflects a 
physiological response to a psychological challenge that is a marker of the ability of the heart to 
engender an adaptive physiological adjustment to an environmental demand.  Importantly, 
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attenuated CV reactivity to mental stress was explanatory of adverse outcomes independently of 
established prognostic markers.  Further research is needed to determine whether CV reactivity 
may provide a novel and unique marker of left ventricular systolic reserve that may be useful in 
risk stratification.   
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